EGFR-targeted pill after surgery for early lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with non-small cell lung cancer, with a specific type called adenocarcinoma (or mostly non-squamous).
- Your cancer is at an early stage (IA2 to IIB) and was completely removed with surgery.
- Your tumor has a specific EGFR gene change (like exon 19 deletion or L858R).
- You have not had any prior cancer treatments like radiation, chemo, or targeted therapy.
- You are generally in good health (able to care for yourself, ECOG 0-1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a type of targeted therapy pill (called a third-generation EGFR-TKI) works when taken after surgery for early-stage non-small cell lung cancer that has certain high-risk features and an EGFR mutation. It aims to see if this treatment can help prevent the cancer from coming back.
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This trial tests whether taking aumolertinib (a pill that targets specific EGFR mutations) after lung cancer surgery helps prevent the cancer from coming back. It is for people with early-stage non-small cell lung cancer that has an EGFR mutation and has been completely removed.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.